Infectious Disease Institute

Infectious Disease

Michael S. Gilmore, PhD

James Chodosh, MD, MPH
Marlene Durand, MD

Paulo Bispo, PhD

See a list of Infectious Disease faculty

The Infectious Disease Institute is a Harvard-wide initiative that operates in conjunction with the NIH-sponsored Harvard-wide Program on Antibiotic Resistance/Boston Area Antibiotic Resistance Network. This alliance promotes interdisciplinary collaboration between Harvard-affiliate hospitals and industry partners to screen and validate new compounds and for microbial infections—many of which can affect the eye. Members of the Infectious Disease Institute also explore the cellular mechanisms of infection (including host-pathogen interactions) and the genetics of microbial pathogens (such as viruses, bacteria, and fungi) to better understand the proliferation and spread of antibiotic resistance and identify novel therapeutic targets.

Major Research Breakthroughs

In the last 20 years, our faculty have speaheaded many new innovations and advances in the field. Notably, they have: 

  • Established a 10,000-strain repository of clinical isolates and new molecular-based infection diagnostics to improve eye care
  • Developed a new rapid PCR-based diagnostic test for the leading causes of infectious uveitis
  • Identified a mechanism for the evolution of novel adenoviruses that cause epidemic keratoconjunctivitis
  • Pioneered new comparative and functional genomics technologies to discover how staphylococci and streptococci infect the ocular surface
  • Traced the origins of antibiotic resistance in a leading multidrug-resistant hospital pathogen to the emergence of land animals, 450 million years ago
  • Identified the molecule dynamin 2 as a key regulator of adenovirus trafficking, affecting both viral replication and inflammation, and identified a unique viral trafficking pathway in human corneal fibroblasts involving dynamin 2

2020 Vision: Promising Areas For Future Research

Our investigators aim to develop promising new compounds to fight the leading causes of multidrug-resistant infections, including staph and other related bacteria; and to develop new technologies, such as the Nanostring Project, which aims to develop a rapid diagnostic technology that would allow for early detection of corneal infection before scarring or blindness occurs.